PAI
RVNC

Palo Alto Investors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Palo Alto Investors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,611,787
Closed -$8.37M – 47
2024
Q3 		$8.37M Sell
1,611,787
-3,645,299
-69% -$18.1M 1.09% 19
2024
Q2 		$13.5M Buy
5,257,086
+9,082
+0.2% +$31K 1.57% 13
2024
Q1 		$25.8M Buy
5,248,004
+10,720
+0.2% +$63.5K 2.91% 12
2023
Q4 		$46M Buy
5,237,284
+8,675
+0.2% +$71.1K 4.15% 8
2023
Q3 		$60M Hold
5,228,609
– – 5.67% 7
2023
Q2 		$132M Sell
5,228,609
-41,600
-0.8% -$1.3M 10.69% 3
2023
Q1 		$170M Sell
5,270,209
-13,400
-0.3% -$418K 14.06% 2
2022
Q4 		$97.5M Buy
5,283,609
+878,570
+20% +$20.1M 8.32% 7
2022
Q3 		$119M Hold
4,405,039
– – 9.4% 5
2022
Q2 		$60.9M Sell
4,405,039
-10,650
-0.2% -$164K 5.31% 8
2022
Q1 		$86.1M Buy
4,415,689
+46,323
+1% +$703K 6.66% 7
2021
Q4 		$71.3M Buy
4,369,366
+1,167,500
+36% +$19.5M 4.56% 9
2021
Q3 		$89.2M Hold
3,201,866
– – 5.38% 9
2021
Q2 		$94.9M Hold
3,201,866
– – 5.23% 8
2021
Q1 		$89.5M Buy
3,201,866
+528,553
+20% +$14.6M 5.1% 8
2020
Q4 		$75.8M Buy
2,673,313
+678,408
+34% +$17.6M 3.97% 10
2020
Q3 		$50.2M Buy
1,994,905
+290,533
+17% +$7.62M 2.75% 12
2020
Q2 		$41.6M Buy
1,704,372
+1,088,667
+177% +$21.5M 2.5% 15
2020
Q1 		$9.11M Buy
615,705
+527,115
+595% +$10.9M 0.76% 20
2019
Q4 		$1.44M Buy
+88,590
New +$1.37M 0.08% 28
2014
Q4 		– Sell
-80,369
Closed -$1.55M – 48
2014
Q3 		$1.55M Sell
80,369
-11,300
-12% -$295K 0.12% 38
2014
Q2 		$3.12M Hold
91,669
– – 0.23% 36
2014
Q1 		$2.89M Buy
+91,669
New +$2.86M 0.24% 29

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Palo Alto Investors's RVNC Position: Q4 2024 in Review

Palo Alto Investors sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 1,611,787 shares — an estimated $8.37M sold.

Palo Alto Investors first reported a position in RVNC in Q1 2014 and held it in 23 quarters. The position peaked at $170M in Q1 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Palo Alto Investors reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Palo Alto Investors sold 1,611,787 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $8.37M.
  • Palo Alto Investors first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 23 quarters.
  • Palo Alto Investors's Revance Therapeutics, Inc. position peaked at $170M in Q1 2023.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Palo Alto Investors's 13F filing for Q4 2024, filed 14 Feb 2025.